Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Nemer

Clinical Cardiac Electrophysiology Columbus, OH Medical Doctor

NPI 1558709857 CMS profile 407610

3705 Olentangy River Rd Ste 100, Columbus, OH 43214

Open in the dashboard

General payments

$97,340

136 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Nemer of Columbus, OH is reported in the CMS Open Payments database as having received $97,340 across 136 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,125 13
2024 General $1,513 20
2023 General $2,335 17
2022 General $2,060 20
2021 General $77,842 11
2020 General $8,037 15
2019 General $4,428 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Nemer
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to David Nemer were reported at $1,125. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year David Nemer Clinical Cardiac Electrophysiology median Middle half National median
2019 $4,428 $2,361 $585–$8,260 $163
2020 $8,037 $993 $247–$4,351 $114
2021 $77,842 $1,185 $326–$4,739 $132
2022 $2,060 $2,073 $554–$6,789 $149
2023 $2,335 $2,568 $759–$8,159 $160
2024 $1,513 $2,557 $703–$7,403 $164
2025 $1,125 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $62,319 42 payments
  2. Medtronic, Inc. $26,711 19 payments
  3. Medtronic Vascular, Inc. $3,836 31 payments
  4. Boston Scientific Corporation $3,460 28 payments
  5. Biosense Webster, Inc. $734 8 payments
  6. Kestra Medical Technology Services, Inc. $183 3 payments
  7. E.R. Squibb & Sons, L.L.C. $36 2 payments
  8. Atricure, Inc. $24 1 payment
  9. Philips Electronics North America Corporation $24 1 payment
  10. Ethicon US, LLC $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $83,647 6 payments
  2. Travel and Lodging $6,750 37 payments
  3. Food and Beverage $6,597 91 payments
  4. Education $346 2 payments
Products named General payments · program years 2019–2025
  1. Ensite Cardiac Mapping System $1,638 18 payments
  2. General - Therapies $1,049 6 payments
  3. EVERA MRI XT DR SURESCAN $836 10 payments
  4. Carto 3 $734 8 payments
  5. ENSITE $507 2 payments
  6. AMPLATZER AMULET $354 2 payments
  7. Rhythmia Mapping System $353 4 payments
  8. Quadra Assura CRT Defibrillator $308 2 payments
  9. WATCHMAN FLX $232 2 payments
  10. General - EP $205 2 payments
  11. Other $2,578 37 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,691

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$585,617

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

38.1%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 375 $400,615
Xarelto Rivaroxaban Brand 136 $143,801
Entresto Sacubitril/Valsartan Brand 13 $10,353
Dofetilide Generic 41 $8,696
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 36 $7,357
Flecainide Acetate Generic 168 $5,588
Metoprolol Succinate Generic 268 $3,761
Amiodarone Hcl Generic 202 $1,973
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 60 $869
Sotalol Sotalol Hcl Brand 24 $523

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$194,376

Medicare's payments for the services billed

Medicare patients

2,373

Average age 77

Services billed

4,503

1,044 women, 1,329 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 59%
Ischemic heart disease 54%
Arthritis 54%
Heart failure 49%
Chronic kidney disease 39%
Diabetes 38%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

136 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record